Cassava Sciences Inc

Research Cassava Sciences Inc (SAVA) on Bullrun: market cap USD 87.92M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSAVA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 87.92M
• Financial periodQ4 2025
• Net income-USD 12.54M
• Free cash flow-USD 10.25M

Valuation Snapshot

latest market cap is USD 87.92M.

About Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.

Frequently asked questions

What is Cassava Sciences Inc's market cap?

Cassava Sciences Inc's market capitalization is USD 87.92M.

What does Cassava Sciences Inc do?

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial;